51-Year Market Veteran Reveals Stunning "Crash Profit Trades"
In the last bear market, Dr. Martin Weiss and his team found historical examples of “Crash Profit Trades” that could have produced gains of 103%, 110%, 124%, 134%, 147%, 150%, 157%, 163%, 168%, 174%, 195%, 198%, 243%, and 293%.

Now, in 2022, even larger profits have been possible.

Show me Crash Profit Trades.
>>>
Michael Severino, insider at AbbVie

Michael Severino Insider Information

Vice Chairman of AbbVie
Dr. Michael Severino is Vice Chairman and President, responsible for research and development and the corporate strategy office. He previously served as Executive Vice President, Research & Development and Chief Scientific Officer of AbbVie.

Prior to joining AbbVie in 2014, Dr. Severino was Senior Vice President, Global Development and Chief Medical Officer at Amgen, Inc. During his time at Amgen, he served in roles of increasing responsibility across a broad range of therapeutic areas including oncology, inflammation, neuroscience, cardiovascular and metabolic disorders. 

Dr. Severino serves on the Board of Directors for Avantor and the Board of Trustees for the Field Museum. At AbbVie, he is the executive chair of the Black Business Network Employee Resource Group. 

He earned a bachelor’s degree in biochemistry from the University of Maryland, College Park and a doctorate in medicine from The Johns Hopkins University in Baltimore, Maryland, U.S.A.  Dr. Severino completed his residency and fellowship training at the Massachusetts General Hospital and Harvard Medical School in Boston, Massachusetts, U.S.A. 

What is Michael Severino's net worth?

The estimated net worth of Michael Severino is at least $21.69 million as of May 23rd, 2022. Dr. Severino owns 152,103 shares of AbbVie stock worth more than $21,689,888 as of August 13th. This net worth evaluation does not reflect any other assets that Dr. Severino may own. Learn More about Michael Severino's net worth.

How do I contact Michael Severino?

The corporate mailing address for Dr. Severino and other AbbVie executives is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. AbbVie can also be reached via phone at (847) 932-7900. Learn More on Michael Severino's contact information.

Has Michael Severino been buying or selling shares of AbbVie?

Michael Severino has not been actively trading shares of AbbVie over the course of the past ninety days. Most recently, Michael Severino sold 79,801 shares of the business's stock in a transaction on Monday, May 23rd. The shares were sold at an average price of $150.90, for a transaction totalling $12,041,970.90. Following the completion of the sale, the insider now directly owns 152,103 shares of the company's stock, valued at $22,952,342.70. Learn More on Michael Severino's trading history.

Who are AbbVie's active insiders?

AbbVie's insider roster includes Carlos Alban (Vice Chairman), Roxanne Austin (Director), Nicholas Donoghoe (SVP), Brian Durkin (VP), Richard Gonzalez (CEO), Henry Gosebruch (EVP), Robert Michael (Vice Chairman), Scott Reents (Sr. VP & CFO ), Timothy Richmond (EVP), Azita Saleki-Gerhardt (EVP), Laura Schumacher (Vice Chairman), Michael Severino (Vice Chairman), Elaine Sorg (SVP), Jeffrey Stewart (EVP), and Carrie Strom (SVP). Learn More on AbbVie's active insiders.

Are insiders buying or selling shares of AbbVie?

During the last year, insiders at the sold shares 18 times. They sold a total of 1,054,001 shares worth more than $147,165,681.47. The most recent insider tranaction occured on May, 23rd when Vice Chairman Michael Severino sold 79,801 shares worth more than $12,041,970.90. Insiders at AbbVie own 0.1 % of the company. Learn More about insider trades at AbbVie.

Information on this page was last updated on 5/23/2022.

Michael Severino Insider Trading History at AbbVie

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/23/2022Sell79,801$150.90$12,041,970.90152,103View SEC Filing Icon  
5/16/2022Sell100,000$154.45$15,445,000.00152,103View SEC Filing Icon  
5/9/2022Sell100,000$150.28$15,028,000.00152,103View SEC Filing Icon  
5/6/2022Sell100,000$150.81$15,081,000.00152,103View SEC Filing Icon  
8/17/2018Sell50,000$97.52$4,876,000.00111,481View SEC Filing Icon  
11/10/2017Sell25,633$94.69$2,427,188.77114,922View SEC Filing Icon  
See Full Table

Michael Severino Buying and Selling Activity at AbbVie

This chart shows Michael Severino's buying and selling at AbbVie by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AbbVie Company Overview

AbbVie logo
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Read More

Today's Range

Now: $142.60
Low: $140.27
High: $143.09

50 Day Range

MA: $146.89
Low: $137.62
High: $154.14

2 Week Range

Now: $142.60
Low: $105.56
High: $175.91

Volume

5,208,659 shs

Average Volume

5,923,121 shs

Market Capitalization

$252.13 billion

P/E Ratio

20.20

Dividend Yield

3.97%

Beta

0.7
Potential 500% Return From A Unique $1 Asset?
Millions are rushing towards life at “Ground Zero”. 

A frightening new financial reality that has the potential to erase the wealth of millions. It’s largely avoidable if you know what to look for.

It all hinges on a single $1 asset that skyrockets during strange times like these. 

Discover it now
>>>